COVID-19 vaccine effectiveness
(Randomized evidence)
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04683484 Nanogen Pharmaceutical Biotechnology JSC Nguyen T, SSRN, 2021 Full text Full text Commentary Commentary |
Protein subunit |
Nanocovax 25 mcg Nanocovax 50 mcg |
Nanocovax 75 mcg |
RCTPhase 1 | Healthy HIV-negative and seronegative adults at a single center in Vietnam | N=60 |
Some concerns Details |
|
|
NCT04400838 AstraZeneca + University of Oxford Voysey M, Lancet, 2020 COV002 Full text Commentary |
Non replicating viral vector |
ChAdOx1 LD/SD ChAdOx1 SD/SD |
Placebo |
RCTPhase 2/3 | Healthy adults in 18 centres in the UK | N=10673 |
Some concerns Details |
|
|
ISRCTN89951424 AstraZeneca + University of Oxford Voysey M, Lancet, 2020 COV003 Full text Commentary |
Non replicating viral vector |
ChAdOx1 |
Placebo |
RCTPhase 3 | Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil | N=10002 |
Some concerns Details |
|